ERBB2 P780_Y781insGSP

CI-VAR-00003405Explore in graph →CIViC 5249

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ERBB2 L755P OR ERBB2 G776V OR ERBB2 G776delinsVC OR ERBB2 P780_Y781insGSP	Zongertinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID12563 In the multicohort phase 1b Beamion LUNG-1 trial (NCT04886804) of zongertinib in HER2-mutant NSCLC, three cohorts were evaluated by mutation type and prior therapy. In cohort 1 (n = 75; HER2-TKD mutat… (full text at CIViC) PMID 40293180 · Heymach et al., 2025 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.